Novartis has scaled up manufacturing of wet age-related macular degeneration (AMD) monoclonal antibody RTH258 ahead of a potential regulatory submission next year.
Ohr Pharmaceutical Inc. has halted activities at the laboratory in San Diego, California where research on its sustained release delivery technology was carried out.
Lucentis biosimilar developer Formycon saw its share price jump 16% days after Pfizer abandoned efforts to create a rival version of Roche's blockbuster eye drug.
A $350m investment will make Regeneron’s Limerick plant “the largest-scale bulk biologics production facility in Ireland,” the firm says, and add a further 200 jobs.
A biosimilar of Roche’s Lucentis could offer a safer universal treatment for wet AMD than off-label use of Avastin - as recommended by the WHO - according to Pfenex.